Skip to main content

Table 6 Association between different CYP2C9, CYP1A2, CYP3A4 and CYP2C19 SNP genotypes and the clinico-pathological features of breast cancer (BC)

From: Association of CYP gene polymorphisms with breast cancer risk and prognostic factors in the Jordanian population

Clinical features CYP2C9 CYP1A2 CYP1B1 CYP3A4 CYP2C19
rs1799853 rs762551 rs10175368 rs35599367 rs4244285
Body mass index b
n = 221
0.078 0.178 0.552 0.286 0.834
Age at first pregnancy b
n = 195
0.144 0.292 0.179 0.032 0.785
Age at BC diagnosis b
n = 221
0.511 0.675 0.295 0.391 0.132
Allergy a
n = 221
0.721 0.927 0.859 0.146 0.920
Age at menarche b
n = 221
0.834 0.738 0.905 0.869 0.931
Breastfeeding status a
n = 221
0.250 0.450 0.196 0.009 0.161
Age at menopause b
n = 108
0 .356 0 .034 0 .554 0 .161 0 .266
Family history a
n = 221
0.562 0.167 0.521 0.494 0.294
Co-morbidity a
n = 221
0.659 0.456 0.774 0.822 0.349
Smoking a
n = 216
0.305 0.705 0.899 0.341 0.528
Pathological features
Progesterone receptor status a
n = 198
0.213 0.118 0.378 0.554 0.213
Estrogen receptor status a
n = 191
0.409 0.208 0.286 0.511 0.409
Human epidermal growth factor receptor 2 marker (HER2) a
n = 139
0.495 0.028 0.109 0.566 0.495
Heteromolecular BC markersa
n = 138
0.691 0.043 0.024 0.914 0.081
Tumor differentiation a
n = 197
0.285 0.577 0.498 0.734 0.285
Axillary lymph nodes a
n = 221
0.956 0.587 0.179 0.346 0.956
Tumor stage a
n = 208
0.743 0.153 0.469 0.048 0.743
Histology classification a
n = 209
0.708 0.011 0.238 0.118 0.708
Tumor size b
n = 208
0.407 0.433 0.991 0.318 0.407
Lymph node involvement a
n = 221
0.194 0.001 0.406 0.516 0.194
  1. a Pearson’s chi-squared test was used to determine genotype-phenotype association
  2. b Analysis of variance (ANOVA) test was used to determine genotype-phenotype association
  3. P-Value < 0.0045 considered as significant